Novo, Lilly Lower GLP-1 Prices, ‘Enabling’ Medicare, Medicaid Coverage In Obesity

 
• By Cathy Kelly
  
Novo CEO Mike Doustdar and Lilly CEO David Ricks announced US pricing deals for GLP-1 agonists in obesity during a White House event. (Screenshot of White House Broadcast)

More from Pricing Debate

More from Market Access